Key Highlights
•
A new oral form of the chemotherapy drug paclitaxel (called DHP107) was tested against the standard intravenous (IV) version for treating advanced breast cancer. This is important because the oral pill could be more convenient for patients and avoids the serious allergic reactions and nerve damage often linked to IV infusions.
Source →
•
For lung cancer patients with specific genetic mutations, adding standard chemotherapy to the targeted drug aumolertinib significantly delayed cancer progression compared to the targeted drug alone. This finding provides a new, more effective treatment strategy for a group of patients who typically don’t respond as well to standard targeted therapies.
Source →
•
A large European study found that lung scarring (interstitial lung disease) linked to certain autoimmune diseases often has a severe pattern and progresses quickly. The research suggests that drugs like rituximab may help preserve lung function, highlighting the need for early diagnosis and personalized treatment.
Source →
•
A study of over 2,200 patients with cardiac amyloidosis, a condition where protein builds up in the heart, shows it can cause heart failure across all levels of heart pumping strength. Combining different heart imaging measurements provides a much better way to predict a patient’s outcome than looking at pumping strength alone.
Source →
•
The antiviral pill nirmatrelvir/ritonavir (Paxlovid) was found to be safe and effective at a lower dose for COVID-19 patients with severe kidney disease, including those on dialysis. This is crucial as these high-risk patients were previously underserved due to concerns about drug accumulation from their impaired kidney function.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
